Agoraphobia Treatment Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Agoraphobia Treatment Market Trends and Insights

Increasing Diagnosis and Treatment-Seeking for Agoraphobia and Panic Disorder

The global burden of anxiety disorders has increased faster than many care systems can absorb. The 2026 Global Burden of Disease analysis reported 1.17 billion prevalent mental disorder cases in 2023, 95.5% higher than the 1990 count.^{[1]Dan Vigo et al., “Updated Trends in the Global Prevalence and Burden of Mental Disorders, 1990-2023, A Systematic Analysis for the Global Burden of Disease Study 2023,” The Lancet, thelancet.com.} The World Health Organization estimates that 4.4% of the global population lives with an anxiety disorder, while only 1 in 4 affected people receive treatment.^{[2]World Health Organization, “Over a Billion People Living with Mental Health Conditions, Services Require Urgent Scale-Up,” WHO News, who.int.} In the United States, panic disorder affects 2.7% of adults in a given year and 4.7% over their lifetime. China announced a 2025-2027 plan to expand outpatient mental and sleep disorder services across prefecture-level cities. The Agoraphobia treatment market benefits when health systems identify people with existing symptoms and route them into formal treatment, rather than from changes in disease prevalence.

Guideline-Supported Adoption of CBT, Exposure Therapy, and SSRIs

Clinical guidelines support cognitive behavioral therapy, exposure therapy, SSRIs, and SNRIs for panic disorder with agoraphobia. The WFSBP guideline identifies SSRIs and SNRIs as first-line pharmacological options and cognitive behavioral therapy as the first-line psychotherapy. Germany’s DGPPN guidance recommends citalopram, escitalopram, paroxetine, sertraline, and venlafaxine as first-line options for panic disorder and agoraphobia. A 2025 review of Brazilian Psychiatric Association guidance identified high-grade evidence for SSRIs and SNRIs, while tricyclic antidepressants had moderate evidence due to adverse-event concerns.^{[3]Borwin Bandelow et al., “World Federation of Societies of Biological Psychiatry Guidelines for Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders, Version 3,” World Journal of Biological Psychiatry, tandfonline.com.} These aligned recommendations support more consistent prescribing, strengthen the role of pharmacotherapy alongside psychotherapy, and shift treatment patterns away from long-term benzodiazepine use toward established SSRI and SNRI therapies within the Agoraphobia treatment market.

Digital CBT, Telepsychiatry, and Virtual Reality Exposure Delivery

Digital delivery can reduce a key access barrier in agoraphobia care, making it increasingly important to the Agoraphobia treatment market. Germany’s digital health framework includes 5 reimbursable digital therapeutics for panic disorder and agoraphobia when prescribed through statutory insurance. In the United States, the 2025 CMS Physician Fee Schedule introduced reimbursement codes for FDA-cleared digital mental health treatments, creating a payment route for clinician-supervised digital care.^{[4]K. K. Y. Kan et al., “An Automated Virtual Reality Cognitive-Behavioural Preventive Intervention for Adults with Agoraphobic Symptoms,” PMC, ncbi.nlm.nih.gov.} Freespira received FDA 510(k) clearance in May 2025 for use in adolescents aged 13-17, and its reported clinical data showed a 54% mean reduction in panic disorder symptom severity and a 45% remission rate within 28 days. A 2025 Hong Kong trial of adapted gameChange found significant reductions in agoraphobic avoidance symptoms in a nonclinical population, while a 2025 meta-analysis found that therapist-guided digital cognitive behavioral therapy performed comparably with face-to-face therapy and unguided programs produced weaker results.

Homebound Patient Demand for Care Delivered Outside Traditional Clinics

Agoraphobia can prevent people from seeking in-person care because the disorder involves avoidance of places perceived as difficult to leave. A 2025 pilot trial found that a blended mobile and virtual reality intervention for panic disorder and agoraphobia produced stronger remission results at 6-week follow-up than a stress-education control and showed that providers could deliver a fully remote approach without direct in-person therapist contact. Freespira launched its FST5 device in February 2026 with integrated sensor and display functions, Wi-Fi and cellular connectivity, and a hospital-grade NDIR CO₂ module. This model combines capnometry-guided respiratory intervention with video coaching at home. Home-based options could reach patients who are underrepresented in clinical registries and less likely to attend outpatient visits in the Agoraphobia treatment market.

Mental-Health Stigma and Delayed Presentation

Stigma delays when many people seek mental health care. In Japan, insurance-covered cognitive behavioral therapy reached only 0.14% of the country’s 6.03 million psychiatric patients in fiscal year 2024. The same study identified a 375-fold difference in utilization between the highest-performing and lowest-performing prefectures. These figures show that insurance coverage alone does not ensure broad use of psychotherapy.

Limited Access, Reimbursement Gaps, and Out-of-Pocket Burden

Payment systems remain uneven across geographies and care settings. Japan recorded 38,045 insurance-covered cognitive behavioral therapy claims for 8,299 patients in fiscal year 2023, down 9.9% from fiscal year 2015, despite wider coverage for anxiety-related conditions. A typical course of cognitive behavioral therapy in North America can require 12-20 sessions, and uncovered session costs of USD 100-300 can discourage adoption. China established a regional digital therapeutics reimbursement policy in Hainan in 2025, but national Basic Medical Insurance coverage for digital therapeutics was not available in the supplied research. People with lower incomes, social isolation, and limited mobility often have the greatest clinical need and the least favorable coverage. These gaps limit the Agoraphobia treatment market’s ability to convert clinical need into paid treatment.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Treatment Modality: Pharmacotherapy Retains the Largest Revenue Base While Combination Care Expands

Pharmacotherapy is expected to account for 52.66% of revenue in 2025, making it the largest component of the agoraphobia treatment market share. This leadership reflects strong evidence supporting SSRIs and SNRIs as scalable first-line options for panic disorder with agoraphobia. Combination and adjunctive treatment is forecast to grow at an 8.15% CAGR through 2031. WFSBP guidance places cognitive behavioral therapy alongside first-line drug treatments for anxiety disorders, while German clinical guidance supports SSRI and SNRI use for panic disorder and agoraphobia.

Digital treatment formats can improve access for patients who cannot receive in-person psychotherapy. A 2025 review found that therapist-guided digital cognitive behavioral therapy delivered significant effects in panic disorder and agoraphobia, with stronger adherence than unguided programs. This supports care models that combine clinician oversight, pharmacotherapy for symptom stabilization, and exposure-based therapy to address avoidance patterns. Reimbursement for digital services can support broader adoption in routine care.

By Pharmacotherapy Class: SSRIs Lead While SNRIs Gain Use in Resistant Presentations

SSRIs are expected to account for 58.76% of pharmacotherapy revenue in 2025 and remain widely used for panic disorder with agoraphobia due to established regulatory approvals and clinical guideline support. SNRIs are forecast to grow at a 9.80% CAGR through 2031. Clinicians use venlafaxine and duloxetine when patients do not achieve adequate results with SSRIs or present with mixed anxiety and depressive symptoms. The WFSBP guideline supports SNRIs as first-line pharmacological options for anxiety disorders, and German guidance identifies venlafaxine as a first-line treatment option.

Tricyclic antidepressants and benzodiazepines play a smaller role because safety concerns can limit use. The 2024 Brazilian guideline review gave SSRIs and SNRIs high evidence ratings, while tricyclic antidepressants received moderate ratings due to adverse-event risks. A 2025 review found that the FDA approved only two new anxiety-disorder medicines from 2008 through 2024, keeping established drug classes central to the agoraphobia treatment market. Buspirone, hydroxyzine, and pregabalin remain adjunctive options for patients who cannot tolerate antidepressants or receive treatment in primary care.

By Route of Administration: Oral Therapies Dominate While Intranasal Delivery Develops

Oral treatments are expected to account for 84.34% of revenue in the agoraphobia treatment market in 2025, supported by generic SSRIs and SNRIs and the convenience of daily self-administration. Intranasal therapies are forecast to expand at a 10.45% CAGR through 2031. Johnson & Johnson received FDA approval in January 2025 for SPRAVATO as stand-alone monotherapy for adults with major depressive disorder who had not responded adequately to at least two oral antidepressants. Although the indication applies to depression, the approval created a regulatory and commercial reference point for intranasal psychiatric therapies.

Eli Lilly announced an agreement in July 2026 to acquire AtaiBeckley for USD 2.8 billion upfront, with up to USD 1.0 billion in contingent milestone payments. The pipeline included BPL-003, an intranasal synthetic 5-MeO-DMT candidate in Phase 3 for treatment-resistant depression with FDA Breakthrough Therapy Designation. Other routes, including transdermal and injectable formats, are used mainly when oral treatment is impractical or rapid stabilization is required. Freespira represents a non-drug, home-based option outside conventional drug-route categories.

By Care Setting: Outpatient Clinics Lead While Specialist Centers Manage Complex Cases

Outpatient psychiatric clinics are expected to account for 84.34% of care-setting revenue in 2025. These clinics manage most diagnoses, prescriptions, and outpatient cognitive behavioral therapy services. Hospitals and specialty mental-health centers are forecast to grow at a 10.56% CAGR through 2031. Their growth reflects rising demand for managing treatment-resistant, adolescent, and severely impaired cases that require multidisciplinary care or stabilization.

Digital and virtual providers are emerging as care settings as payment systems begin recognizing digital mental health services. Germany’s digital health framework supports prescribed digital tools for panic disorder and agoraphobia. Academic centers continue to test new protocols, including the VRExpo study at Johannes Gutenberg University Mainz, which began recruitment in May 2025 and has a primary completion target of August 2026. Japan’s insurance-covered cognitive behavioral therapy reached only 8,299 patients in fiscal year 2023, creating a role for virtual services, primary care, and specialist facilities.

By Distribution Channel: Hospital Pharmacies Lead While Digital Channels Grow

Hospital pharmacies are expected to account for 46.45% of distribution revenue in 2025. They play a key role in initiating acute-phase pharmacotherapy, managing specialty medicines, and dispensing treatments with restricted distribution requirements. Direct-to-patient digital channels are forecast to grow at a 9.56% CAGR through 2031. Prescription digital therapeutics can be activated after clinician authorization without a conventional pharmacy dispensing step.

Specialty pharmacies serve complex prescriptions that require prior authorization, patient support, or adherence monitoring. Otsuka Pharmaceutical and Click Therapeutics launched Rejoyn in Great Britain in June 2025 through select NHS Trusts. Rejoyn is a prescription-only cognitive behavioral therapy digital therapeutic for depressive disorder, and its launch showed how direct digital delivery can bypass physical dispensing for eligible digital products. Wider payer coverage could increase the use of similar distribution structures in the agoraphobia treatment market.

Geography Analysis

North America held 40.45% of global revenue in 2025, the largest regional revenue share. The United States supported regional demand through higher diagnosis rates, private coverage for medicines and outpatient psychotherapy, and FDA regulatory activity. The National Institute of Mental Health reported that 2.7% of U.S. adults had panic disorder in the past year. CMS reimbursement changes in 2025 improved the payment pathway for FDA-cleared digital mental health treatments. Canada and Mexico contributed revenue, although specialist shortages and public-system wait times left unmet need, while the regional system combined branded medicines, generics, digital services, and growing interest in intranasal psychiatric delivery.

Europe is the second-largest regional contributor, led by Germany, the United Kingdom, France, Italy, and Spain. Germany has a developed framework for evidence-based pharmacotherapy and reimbursed digital care for panic disorder and agoraphobia. The United Kingdom’s NICE guideline identifies SSRIs as the preferred pharmacological option for panic disorder with or without agoraphobia and supports cognitive behavioral therapy. France updated its standards for serious anxiety disorders in January 2025 and maintained eligibility criteria for SSRI and SNRI reimbursement. Spain, Italy, and other European markets are supported by awareness programs, public investment in mental health care, and a clearer pathway for prescribed digital services in the Agoraphobia treatment market.

Asia-Pacific is forecast to grow at an 8.58% CAGR through 2031, the fastest regional rate in the Agoraphobia treatment market. Efforts to address underdiagnosis, expand mental health infrastructure, and improve access to generic SSRIs and SNRIs support growth. Japan allocated 8.8% of its health budget to mental health in the supplied research, but insurance-covered cognitive behavioral therapy reached only 0.14% of 6.03 million psychiatric patients in fiscal year 2023. Australia’s Pharmaceutical Benefits Scheme subsidizes SSRIs and SNRIs, while South Korea’s digital therapeutics reimbursement framework was still developing through mid-2026. The Middle East and Africa and South America remained smaller markets due to workforce, insurance, and stigma-related barriers.